Burden of Illness in Irritable Bowel Syndrome Comparing Rome I and Rome II Criteria

Author： Badia X.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.20, Iss.11, 2002-01, pp. : 749-758

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Economic Burden of Irritable Bowel Syndrome: Proposed Strategies to Control Expenditures

By Camilleri M.  

PharmacoEconomics, Vol. 17, Iss. 4, 2000-04 ,pp. : 331-338

Adis International

Access to resources Recommend Favorite

Alosetron and irritable bowel syndrome

By Mayer Emeran A   Bradesi Sylvie  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 11, 2003-11 ,pp. : 2089-2098

Informa Healthcare

Access to resources Recommend Favorite

Irritable Bowel Syndrome

By Spinelli Antonella  

Clinical Drug Investigation, Vol. 27, Iss. 1, 2007-01 ,pp. : 15-33

Adis International

Access to resources Recommend Favorite

Quality of Life in Irritable Bowel Syndrome

By Lea R.   Whorwell P.J.  

PharmacoEconomics, Vol. 19, Iss. 6, 2001-06 ,pp. : 643-653

Adis International

Access to resources Recommend Favorite

Serotonergic modulation and irritable bowel syndrome

By Borman R.  

Expert Opinion on Emerging Drugs, Vol. 6, Iss. 1, 2001-04 ,pp. : 57-68

Informa Healthcare

Access to resources Recommend Favorite